logo
  

Pre-market Movers: BXRX, CNCE, GROM, NRBO, BHIL…

us pre market 053119 09dec22 lt

The following are some of the stocks making big moves in Friday's pre-market trading (as of 06.30 A.M. ET).

In the Green

Baudax Bio, Inc. (BXRX) is up over 54% at $6.30
Concert Pharmaceuticals, Inc. (CNCE) is up over 41% at $6.35
NeuroBo Pharmaceuticals, Inc. (NRBO) is up over 34% at $2.33
Benson Hill, Inc. (BHIL) is up over 27% at $3.33
China Jo-Jo Drugstores, Inc. (CJJD) is up over 22% at $2.68
DocuSign, Inc. (DOCU) is up over 12% at $49.10
EPR Properties (EPR) is up over 7% at $44
ForgeRock, Inc. (FORG) is up over 7% at $23.00
Korea Electric Power Corporation (KEP) is up over 7% at $7.93
HUYA Inc. (HUYA) is up over 6% at $2.99
Zai Lab Limited (ZLAB) is up over 5% at $37.00

In the Red

Grom Social Enterprises, Inc. (GROM) is down over 36% at $2.44
Autolus Therapeutics plc (AUTL) is down over 27% at $2.18
Pharvaris N.V. (PHVS) is down over 15% at $9.74
ENDRA Life Sciences Inc. (NDRA) is down over 14% at $3.05
KWESST Micro Systems Inc. (KWE) is down over 11% at $3.20
Neonode Inc. (NEON) is down over 10% at $4.52
Carvana Co. (CVNA) is down over 10% at $4.42
Lululemon Athletica Inc. (LULU) is down over 7% at $348.01

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT